Protembis

Protembis is a private, clinical-stage medical device company focused on cerebral protection during TAVR procedures. Its lead product, the ProtEmbo Cerebral Protection System (CPS), is designed to filter embolic debris to prevent large, clinically meaningful brain infarcts. The company is currently conducting a pivotal FDA IDE trial, has demonstrated promising safety and efficacy in European studies, and is backed by significant financing from the European Investment Bank and other investors to advance its clinical and commercial goals.

The ProtEmbo Cerebral Protection System (CPS), a next-generation embolic filter device designed to capture debris during TAVR procedures to prevent large, clinically meaningful brain infarcts.

The primary competitor is Boston Scientific's Sentinel Cerebral Protection System, the only FDA-approved device in the space. Protembis aims to compete by demonstrating superior efficacy in preventing large brain lesions via advanced MRI endpoints. Other competitors may include embolic protection devices in development or approved for different indications.